Topic prioritisation

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Decision date

Decision date

Prioritisation programme

Prioritisation programme

Decision

Decision

Showing 1 to 50 of 112

TitlePrioritisation programmeDecisionDecision date
Dabrafenib with trametinib for adjuvant treatment of resected BRAF V600 mutation-positive melanoma in people aged 12 to 17 [TSID11839]Medicines evaluationNot selected
Dronabinol for treating muscle spasticity in multiple sclerosis after 2 treatments [TSID10638]Medicines evaluationNot selected
Dabrafenib for treating unresectable or metastatic BRAF V600 mutation positive melanoma in people 12 to 17 years [TSID12399]Medicines evaluationNot selected
Dabrafenib with trametinib for treating unresectable or metastatic BRAF V600 mutation positive melanoma in people 12 to 17 years [TSID12398]Medicines evaluationNot selected
Ponatinib for treating recurrent or refractory chronic myeloid leukaemia in people 1 to 17 years when another tyrosine kinase inhibitor is unsuitable [TSID12041]Medicines evaluationNot selected
Vedolizumab for treating moderately to severely active Crohn's disease in people 2 to 17 years [TSID12312]Medicines evaluationNot selected
Isavuconazol for treating invasive aspergillosis or mucormycosis in people 1 to 17 years [TSID12284]Medicines evaluationNot selected
SEEG-guided radiofrequency thermocoagulation in refractory epilepsyInterventional proceduresAwaiting decision
Xeomin (botulinum neurotoxin type A) for treating lower or upper limb spasticity in people 2 to 17 years [TSID12297]None selectedNot selected
Lanadelumab for preventing recurrent attacks of hereditary angioedema in people 2 years and over [TSID12298]None selectedNot selected
Ivacaftor–tezacaftor–elaxcaftor and ivacaftor for treating cystic fibrosis with at least 1 F508del mutation in the CFTR gene in people 1 to under 2 years [TSID12295]None selectedNot selected
Vanzacaftor–tezacaftor–deutivacaftor for treating cystic fibrosis with 1 or more responsive mutations in the CFTR gene in people 2 to 5 years [TSID12296]None selectedNot selected
Mercaptamine hydrochloride for treating corneal cystine crystal deposits in people 6 months to under 2 years with cystinosis [TSID12261]None selectedNot selected
Semaglutide for treating type 2 diabetes in people 10 to 17 years [TSID12249]None selectedNot selected
Modified release hydrocortisone capsules for treating adrenal insufficiency in people 12 years and over [TSID12254]None selectedNot selected
Dasiglucagon for treating severe hypoglycaemia caused by type 1 diabetes in people under 6 years [TSID12255]None selectedNot selected
Dermal allograft augmentation in proximal humerus fracture fixationNone selectedAwaiting decision
Ferric citrate for managing iron and serum phosphorus levels in anaemia associated with chronic kidney disease [TSID12221]None selectedNot selected
Oral cabotegravir with rilpivirine for treating HIV-1 in people 12 to 17 years [TSID12214]None selectedNot selected
Long-acting injections of cabotegravir with rilpivirine for treating HIV-1 in people 12 to 17 years [TSID12219]None selectedNot selected
Lutetium (177Lu) oxodotreotide for treating SSTR-positive advanced or inoperable gastroenteropancreatic neuroendocrine tumours in people 12 to 17 years [TSID12154]None selectedNot selected
Risankizumab for treating moderate to severe plaque psoriasis in people 6 to 17 years [TSID12204]None selectedNot selected
Leniolisib for untreated activated phosphoinositide 3-kinase delta syndrome in children 4 to 11 years [TSID12190]None selectedNot selected
Subcutaneous nivolumab–relatlimab for untreated unresectable or metastatic melanoma in people 12 years and over [TSID 12178]None selectedNot selected
Sulthiame for treating self-limiting epilepsy with centrotemporal spikes in children TSID 12106None selectedNot selected
Apremilast for treating juvenile psoriatic arthritis in people 5 to 17 years [TSID12089]None selectedNot selected
Doravirine–islatravir for treating HIV-1 in people with virological suppression on antiretroviral therapy [TSID12173]None selectedNot selected
Ocrelizumab for treating relapsing–remitting multiple sclerosis in people 10 to 17 years [TSID12164]None selectedNot selected
Doravirine–islatravir for treating HIV-1 in people with virological suppression on bictegravir, emtricitabine and tenofovir alafenamide combination treatment [TSID12171]None selectedNot selected
NEMOST growing domino for Neuromuscular early onset scoliosis with Risser 0 in first surgical intentionHealthTechAwaiting decision
Veverimer for treating metabolic acidosis in chronic kidney disease [ID3832]None selectedAwaiting decision
Linaclotide acetate for treating functional constipation in people 6 to 17 years [TSID12125]None selectedNot selected
Vedolizumab for treating moderately to severely active ulcerative colitis in people 2 to 17 years [TSID12134]None selectedNot selected
High resolution anoscopy and laser therapy for intraepithelial neoplasia of the anus in high risk or immunocompromised patientsNone selectedAwaiting decision
Clindamycin for treating bacterial vaginosis in females aged 12 and older [TSID 12127]None selectedNot selected
Ustekinumab for treating moderately to severely active ulcerative colitis in children aged 2 to 17 years [TSID 12128]None selectedNot selected
Berotralstat for preventing recurrent attacks of hereditary angioedema in children aged 2 to 12 years [TSID 12132]None selectedNot selected
Lebrikizumab for treating atopic dermatitis in children [TSID12133]None selectedNot selected
Lebrikizumab for treating atopic dermatitis in children [TSID 12133_TSID 12135]None selectedNot selected
Avatrombopag for treating primary chronic immune thrombocytopenia in people 1 to 17 years [TSID12109]None selectedNot selected
NVK-002 for treating myopia in people 3 to 17 years [TSID11961]None selectedNot selected
Pitolisant for treating narcolepsy in children and young people 6 to 17 years ID6353None selectedNot selected
Entrectinib for treating NTRK fusion-positive solid tumours in people 1 month to 11 years [TSID12116]None selectedNot selected
Selumetinib granules for treating symptomatic and inoperable plexiform neurofibromas associated with type 1 neurofibromatosis in children 1 to 6 years [TSID12092]None selectedNot selected
Evinacumab for treating homozygous familial hypercholesterolemia in children aged 6 months to 11 [TSID11806]None selectedNot selected
Lomitapide for treating homozygous familial hypercholesterolaemia in people 5 to 17 years [TSID 12085]None selectedNot selected
Ustekinumab for the treatment of moderately to severely active Crohn's disease in children [TS ID 11955]None selectedn/a
Mexiletine hydrochloride for treating myotonia in children and adolescents with myotonic disorders [TS ID 11978]None selectedNot selected
Human normal immunoglobulin for preventing infection in chronic lymphocytic leukaemia [TSID12043]None selectedNot selected
Budesonide–glycopyrronium–formoterol fumarate for treating severe asthma in people 12 years and over TS ID 12018None selectedNot selected

Results per page

  1. 10
  2. 25
  3. 50
  4. All